Pharma companies in cancer drug patent stoush

Two pharmaceutical companies are locked in a legal battle over the patent for an anti-cancer drug, with one claiming the patent was altered in order to catch it out.Aventis Pharma SA has applied for an interim order restraining InterPharma (NZ) from suppl

Niko Kloeten
Thu, 29 Apr 2010

Two pharmaceutical companies are locked in a legal battle over the patent for an anti-cancer drug, with one claiming the patent was altered in order to catch it out.

Aventis Pharma SA has applied for an interim order restraining InterPharma (NZ) from supplying the product Docetaxel Ebewe to Pharmac,

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual

Group membership

NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).

View terms and conditions.